OR Royalties Inc. (NYSE:OR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

OR Royalties Inc. (NYSE:ORGet Free Report) has received an average rating of “Moderate Buy” from the ten research firms that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $46.50.

A number of research firms have issued reports on OR. Canadian Imperial Bank of Commerce reiterated an “outperform” rating on shares of OR Royalties in a research report on Wednesday, February 4th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $56.00 target price on shares of OR Royalties in a research note on Friday, April 10th. TD Securities reiterated a “hold” rating on shares of OR Royalties in a research note on Monday, February 23rd. Weiss Ratings reiterated a “buy (b)” rating on shares of OR Royalties in a research note on Monday, December 29th. Finally, Scotiabank raised their target price on shares of OR Royalties from $41.00 to $51.00 and gave the company a “sector perform” rating in a research note on Monday, January 26th.

Read Our Latest Research Report on OR Royalties

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Alps Advisors Inc. acquired a new position in OR Royalties during the third quarter worth $2,649,000. CWA Asset Management Group LLC raised its position in OR Royalties by 112.6% during the third quarter. CWA Asset Management Group LLC now owns 381,747 shares of the basic materials company’s stock worth $15,300,000 after acquiring an additional 202,173 shares in the last quarter. Synergy Asset Management LLC raised its position in OR Royalties by 200.0% during the third quarter. Synergy Asset Management LLC now owns 52,851 shares of the basic materials company’s stock worth $2,118,000 after acquiring an additional 35,234 shares in the last quarter. U S Global Investors Inc. raised its position in OR Royalties by 62.0% during the third quarter. U S Global Investors Inc. now owns 931,076 shares of the basic materials company’s stock worth $37,312,000 after acquiring an additional 356,245 shares in the last quarter. Finally, Navellier & Associates Inc. bought a new stake in OR Royalties during the third quarter worth $1,451,000. Institutional investors and hedge funds own 68.52% of the company’s stock.

OR Royalties Trading Down 0.9%

Shares of OR stock opened at $40.07 on Friday. The company’s fifty day simple moving average is $40.76 and its 200-day simple moving average is $38.22. OR Royalties has a 52 week low of $22.40 and a 52 week high of $48.06. The company has a market cap of $7.51 billion, a PE ratio of 36.76 and a beta of 0.83.

OR Royalties (NYSE:ORGet Free Report) last released its quarterly earnings results on Wednesday, February 18th. The basic materials company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.01. The firm had revenue of $90.47 million for the quarter, compared to the consensus estimate of $90.80 million. OR Royalties had a net margin of 74.30% and a return on equity of 12.41%. Equities research analysts expect that OR Royalties will post 1.37 EPS for the current fiscal year.

OR Royalties Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Tuesday, March 31st were paid a $0.055 dividend. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.5%. OR Royalties’s payout ratio is currently 20.18%.

About OR Royalties

(Get Free Report)

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.

See Also

Analyst Recommendations for OR Royalties (NYSE:OR)

Receive News & Ratings for OR Royalties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OR Royalties and related companies with MarketBeat.com's FREE daily email newsletter.